The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis

Immune checkpoint inhibitor (ICI)-mediated myocarditis is a rare but devastating side effect of cancer immunotherapy with up to 40% mortality and long-term cardiac issues such as arrhythmias and heart failure in affected patients. 1 Moslehi J.J. Salem J.E. Sosman J.A. Lebrun-Vignes B. Johnson D.B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391: 933https://doi.org/10.1016/s0140-6736(18)30533-6 Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar Recently, Axelrod et al. 2 Axelrod M.L. Meijers W.C. Screever E.M. Qin J. Carroll M.G. Sun X. Tannous E. Zhang Y. Sugiura A. Taylor B.C. et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. 2022; 611: 818-826https://doi.org/10.1038/s41586-022-05432-3 Crossref Scopus (46) Google Scholar suggested an auto-antigen-driven mechanism as the immunological basis for this disease. Immune checkpoint inhibitor (ICI)-mediated myocarditis is a rare but devastating side effect of cancer immunotherapy with up to 40% mortality and long-term cardiac issues such as arrhythmias and heart failure in affected patients. 1 Moslehi J.J. Salem J.E. Sosman J.A. Lebrun-Vignes B. Johnson D.B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391: 933https://doi.org/10.1016/s0140-6736(18)30533-6 Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar Recently, Axelrod et al. 2 Axelrod M.L. Meijers W.C. Screever E.M. Qin J. Carroll M.G. Sun X. Tannous E. Zhang Y. Sugiura A. Taylor B.C. et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. 2022; 611: 818-826https://doi.org/10.1038/s41586-022-05432-3 Crossref Scopus (46) Google Scholar suggested an auto-antigen-driven mechanism as the immunological basis for this disease.